Novoheart Beats Faster on R&D Pact with Major Partner

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, January 21, 2020

With advances in safeguarding human health reported every day, it`s gratifying to know that one of the prime movers in this innovation is close to home.

Vancouver-based Novoheart (TSX-Venture:NVH) is a global stem cell biotechnology company. Tuesday, the company revealed the completion of a research and development contract sponsored by a top-10 global pharma.

NVH deliverables will see Novoheart further expand its current testing capabilities of the MyHeart™ Platform by designing and developing a new versatile High-Throughput microplate which will allow the screening of hundreds of drugs using engineered human ventricular Cardiac Tissue Strips (hvCTS).

The MyHeart Platform includes its ‘human heart-in-a-jar’ technology, and provides engineered human cardiac tissue models for testing the efficacy and safety of drugs to predict human responses with more accuracy.

The microplate market is estimated at $980 million.

On the markets, NVH shares rallied five cents, or 8.1%, Tuesday to 67 cents, on impressive volume of 130,000

Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon